Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Marky1 on Dec 05, 2020 9:29pm

Great news

Someone just posted on another sight that the patent can be extended 5 years beyond the allocated date

That means that the patent for Otenaproxesul can be extended to 2036
amazing newshttps://www.drugpatentwatch.com/blog/how-long-do-drug-patents-last/amp/
Comment by bringon10bagger on Dec 06, 2020 9:31am
Great news, very confident in saying with the psoitioning of the science and the team in place NOW, the strategy is well developed and beginning to play out.  ATE is a no brainer investment play..........
Comment by MrMugsy on Dec 06, 2020 11:01am
I think Dan briefly talked to the patent and the 5 years - not that we can get an extra 5 years - but we can get 5 years regardless of the year we start selling.  Does that sound correct?
Comment by themagicbox on Dec 06, 2020 12:28pm
Yes. from biopub (fireside chat). 5 years once the product hits the market.
Comment by Pragmatist on Dec 06, 2020 7:55pm
ttps://camargopharma.com/resources/blog/alkermes-prodrug-for-treatment-of-multiple-sclerosis-nce/   Mugsy, I think your interpretation is correct.  But is it five years, or three years?  I guess it depends on what an "active moiety" is for OTEN. (and whether the quote in the referenced blog is accurate) I think the CEO would know.     "The ...more  
Comment by MrMugsy on Dec 06, 2020 8:57pm
Good question. I can only say that I heard it from Dan in one of the conference calls and he referenced 5 years of protection.  I think he was talking about the orange book w.r.t the patent and then the fact that they'd get 5 years regardless of start date. Sure hope it's 5 !!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities